Quarterly activities and cashflow report
Filed with ASX · · 10 pages · English
§ Company well-funded to execute on commercial launch with cash balance of A$9.6m as at 31 December 2025. MELBOURNE, AUSTRALIA, 29th January 2026: Ovarian Cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to provide the market with an update on its activities in the December 2025 Quarter (the Quarter) as it develops its simple and accurate blood test
Earlier from CLEO Diagnostics
- CLEO Raises $5m to Support U.S. Market Launch
- Trading Halt
- Cleo Strengthens Cash Position with $1.7m R&D Tax Refund
- CLEO Appoints First Key Opinion Leader to Support US Market
- CLEO Significantly Expands Addressable Market
Later from CLEO Diagnostics
- CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
- Appendix 4D and Half Yearly Accounts
- CLEO Optimises Biomarker Panel Ahead of FDA Submission
- Sample Collection Completion for Pivotal US Clinical Trial
- CLEO Commences Kit Manufacturing Ahead of FDA Submission
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics